Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO

Breast Cancer: Targets and Therapy 2022, 14:113-123

Published Date: 29 April 2022